Tuberculosis is a disease
that attacks the lungs and is one of the top ten causes of death in the world.
In 2021 there are 283,000 cases of tuberculosis in Indonesia that have not been
treated. The effectiveness of tuberculosis treatment decreases due to increased
resistant of Mycobacterium tuberculosis. The utilization of herbal plants such
as the rhizome of the temu kunci (Boesenbergia rotunda) can be selected as an
alternative treatment to overcome the problem of resistant. The purpose of this
study was to determine the drug-likeness characteristics of the active
compounds of temu kunci, to determine the interaction between the active
compounds of temu kunci with the target protein Arabinosyltransferase C Enzyme
and InhA, and to determine the active compounds of temu kunci which have the
most potential as antibacteria of M. tuberculosis in silico.
The results of the drug-likeness test showed that nine selected active
compounds of temu kunci complied with the Lipinski rules which were nerol, camphor, cineole,
trans-methyl cinnamate, cis-p-mentha-2,8-dien-1-ol, octanal,(2,4-dinitrophenyl)
hydrazine, pinostrobin chalcone, furan-3-carboxamide 2-methyl-N-(4-morpholyl)-,
and hemanthidine. A
molecular docking test showed that there were four compounds with the most
potential as antibacterials with Arabinosyltransferase C Enzyme target
proteins, which were octanal (2,4-dinitrophenyl) hydrazine,
pinostrobin chalcone, hemanthidine, and furan 3-carboxamide
2-methyl-N-(4-morpholyl- Meanwhile, the seven most potent antibacterial
compounds with InhA target proteins were pinostrobin chalcone, hemanthidine,
trans-methyl cinnamate, octanal (2,4-dinitrophenyl) hydrazine, nerol, cis-p-metha-2,8-dien-1-ol,
and furan-3-carboxamide 2-methyl-N-(5-morpholyl)-. Further research is needed
to study and clarify the specific inhibition mechanism and the toxicity of each
of the active compounds of temu kunci.
Keywords: tuberculosis, resistant,
Arabinosyltransferase C Enzyme, InhA